ROCKET PHARMACEUTICALS, INC.
RCKT, RCKTW · Pharmaceutical Preparations · 109.2M shares · +18%/yr ↑ dilution · EDGAR filings ↗
Reference price $3.09 · est. market cap ~$337M — last insider sale, 2026-05-21 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — gene-therapy biotech, heavy burn, funded.
Strengths
- Liquidity — current ratio 6.4 (66th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- No interest coverageInterest coverage -122.55 (cannot cover interest)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Cash burnNegative free cash flow (-190.5M)
- Chronic dilutionShare count +18%/yr over 4y (dilution, book value/share -68%)
- Insider sellingInsider selling — 14 open-market sale(s) by 4 insider(s) (cluster of 4 insiders, ~$397,075, last 6mo) Form 4 ↗
- Notable holderHeld by 6 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, RENAISSANCE TECHNOLOGIES LLC +3 more (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-05-05 — PHASE2 · Fanconi Anemia Complementation Group A
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-80.5%
Return on assets
-67.5%
Interest coverage
-122.6×
Current ratio
6.4×
Free cash flow
-$190M
EBITDA
-$223M
Tangible book value
$213M
Cash & investments
$189M
Cash runway
4q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-21 | Shah Gaurav | Option exercise | 76K | $1.69 |
| 2026-05-21 | Shah Gaurav | Sell | 56K | $3.09 |
| 2026-05-19 | Shah Gaurav | Sell | 2.4K | $3.01 |
| 2026-05-19 | Wilson Martin | Sell | 662 | $3.01 |
| 2026-05-19 | Militello John | Sell | 384 | $3.01 |
| 2026-05-13 | Wilson Martin | Sell | 3.4K | $3.61 |
| 2026-05-13 | Shah Gaurav | Sell | 2.7K | $3.61 |
| 2026-05-13 | Militello John | Sell | 855 | $3.61 |
| 2026-05-07 | Chaudhuri Sarbani | Sell | 18K | $3.84 |
| 2026-02-18 | Militello John | Sell | 1.2K | $3.34 |
| 2026-02-18 | Shah Gaurav | Sell | 6.0K | $3.34 |
| 2026-02-18 | Wilson Martin | Sell | 1.4K | $3.34 |
| 2026-02-13 | Wilson Martin | Sell | 12K | $3.31 |
| 2026-02-13 | Militello John | Sell | 3.7K | $3.31 |
| 2026-02-13 | Shah Gaurav | Sell | 12K | $3.31 |
| 2026-02-11 | Shah Gaurav | Grant | 286K | — |
| 2026-02-11 | Militello John | Grant | 30K | — |
| 2026-02-11 | Wilson Martin | Grant | 312K | — |
| 2026-02-11 | Rizvi Syed Ali-aamir | Grant | 62K | — |
| 2026-02-11 | Stevens Christopher James | Grant | 62K | — |
| 2026-02-11 | Chaudhuri Sarbani | Grant | 126K | — |
| 2026-01-02 | Bjork Elisabeth | Buy | 10K | $3.44 |
| 2025-11-18 | Militello John | Sell | 1.1K | $2.98 |
| 2025-11-18 | Schwartz Jonathan David | Sell | 2.5K | $2.98 |
| 2025-11-18 | Shah Gaurav | Sell | 6.3K | $2.98 |
| 2025-11-18 | Wilson Martin | Sell | 1.6K | $2.98 |
| 2025-11-03 | Wilson Martin | Grant | 100K | — |
| 2025-10-14 | Militello John | Sell | 20K | $3.96 |
| 2025-10-14 | Militello John | Sell | 5.5K | $3.96 |
| 2025-10-14 | Militello John | Sell | 3.0K | $3.97 |
| 2025-10-14 | Militello John | Sell | 558 | $3.98 |
| 2025-10-06 | Rizvi Syed Ali-aamir | Grant | 283K | — |
| 2025-10-06 | Rizvi Syed Ali-aamir | Grant | 63K | — |
| 2025-09-24 | Fong Peter | Grant | 23K | — |
| 2025-09-24 | Fong Peter | Grant | 30K | — |
| 2025-09-19 | RTW INVESTMENTS, LP | Option exercise | 1.0M | $40.03 |
| 2025-09-19 | RTW INVESTMENTS, LP | Other | 1.0M | $3.10 |
| 2025-09-19 | RTW INVESTMENTS, LP | Option exercise | 41K | $19.09 |
| 2025-09-19 | RTW INVESTMENTS, LP | Other | 41K | $3.10 |
| 2025-09-19 | RTW INVESTMENTS, LP | Option exercise | 59K | $17.81 |
| 2025-09-19 | RTW INVESTMENTS, LP | Other | 59K | $3.10 |
| 2025-09-08 | Militello John | Grant | 40K | — |
| 2025-09-08 | Wilson Martin | Grant | 150K | — |
| 2025-09-08 | Schwartz Jonathan David | Grant | 80K | — |
| 2025-08-27 | Bjork Elisabeth | Buy | 10K | $3.41 |
| 2025-08-19 | Schwartz Jonathan David | Sell | 805 | $3.00 |
| 2025-08-19 | Militello John | Sell | 361 | $3.00 |
| 2025-08-19 | Wilson Martin | Sell | 588 | $3.00 |
| 2025-08-18 | Wilson Martin | Sell | 1.0K | $3.06 |
| 2025-08-18 | Schwartz Jonathan David | Sell | 1.7K | $3.06 |
| 2025-08-18 | Shah Gaurav | Tax withheld | 2.2K | $3.05 |
| 2025-08-18 | Militello John | Sell | 699 | $3.06 |
| 2025-08-14 | Schwartz Jonathan David | Sell | 11K | $3.02 |
| 2025-08-14 | Militello John | Sell | 7.0K | $3.02 |
| 2025-08-14 | Wilson Martin | Sell | 12K | $3.02 |
| 2025-08-04 | Stevens Christopher James | Grant | 407K | — |
| 2025-07-03 | Ondrey Aaron | Sell | 1.5K | $2.88 |
| 2025-06-18 | WONG RODERICK | Grant | 18K | — |
| 2025-06-18 | Pratumsuwan Piratip | Grant | 30K | — |
| 2025-06-18 | GRANADILLO PEDRO P | Grant | 30K | — |
| 2025-06-18 | GRANADILLO PEDRO P | Grant | 25K | — |
| 2025-06-18 | Dolsten Mikael | Grant | 30K | — |
| 2025-06-18 | Makker Gotham | Grant | 30K | — |
| 2025-06-18 | Makker Gotham | Grant | 19K | — |
| 2025-06-18 | Malik Fady Ibraham | Grant | 30K | — |
| 2025-06-18 | BOESS CARSTEN | Grant | 30K | — |
| 2025-06-18 | Bjork Elisabeth | Grant | 30K | — |
| 2025-06-18 | SOUTHWELL DAVID P | Grant | 30K | — |
| 2025-06-18 | WONG RODERICK | Grant | 30K | — |
| 2025-05-20 | Shah Gaurav | Sell | 2.3K | $6.45 |
| 2025-05-20 | Militello John | Sell | 357 | $6.45 |
| 2025-05-20 | Schwartz Jonathan David | Sell | 801 | $6.45 |
| 2025-05-20 | Patel Kinnari | Sell | 767 | $6.45 |
| 2025-05-20 | Wilson Martin | Sell | 587 | $6.45 |
| 2025-05-16 | Militello John | Sell | 655 | $6.53 |
| 2025-05-16 | Patel Kinnari | Sell | 1.4K | $6.53 |
| 2025-05-16 | Schwartz Jonathan David | Sell | 1.6K | $6.53 |
| 2025-05-16 | Shah Gaurav | Sell | 3.6K | $6.53 |
| 2025-05-16 | Wilson Martin | Sell | 946 | $6.53 |
| 2025-04-22 | Militello John | Sell | 718 | $7.16 |
| 2025-04-10 | Shah Gaurav | Buy | 20K | $5.08 |
| 2025-04-09 | Patel Kinnari | Buy | 21K | $4.70 |
| 2025-04-04 | Ondrey Aaron | Sell | 7.5K | $5.29 |
| 2025-03-05 | Dolsten Mikael | Other | 14K | — |
| 2025-02-25 | Schwartz Jonathan David | Sell | 6.5K | $10.58 |
| 2025-02-21 | Patel Kinnari | Sell | 6.1K | $10.58 |
| 2025-02-21 | Wilson Martin | Sell | 3.2K | $10.58 |
| 2025-02-21 | Militello John | Sell | 2.7K | $10.58 |
| 2025-02-21 | Shah Gaurav | Sell | 16K | $10.58 |
| 2025-02-11 | Wilson Martin | Grant | 90K | — |
| 2025-02-11 | Shah Gaurav | Grant | 82K | — |
| 2025-02-11 | Schwartz Jonathan David | Grant | 80K | — |
| 2025-02-11 | Patel Kinnari | Grant | 58K | — |
| 2025-02-11 | Ondrey Aaron | Grant | 90K | — |
| 2025-02-11 | Militello John | Grant | 20K | — |
| 2025-01-23 | Militello John | Sell | 896 | $10.38 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07527975 ↗ | Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102 Fanconi Anemia | — | Enrolling By Invitation | 2038-05-01 |
| NCT06282432 ↗ | Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) Leukocyte Adhesion Deficiency | — | Active Not Recruiting | 2036-10-04 |
| NCT04437771 ↗ | Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy Fanconi Anemia Complementation Group A, Fanconi Anemia | — | Active Not Recruiting | 2034-01-17 |
| NCT06644742 ↗ | PKP2-ACM Natural History Study Cardiomyopathies, Heart Diseases | — | Recruiting | 2030-12-01 |
| NCT06214507 ↗ | Danon Disease Natural History Study Danon Disease | — | Recruiting | 2029-12-01 |
| NCT07137338 ↗ | A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy Dilated Cardiomyopathy (DCM) | PHASE1 | Recruiting | 2029-06-01 |
| NCT05885412 ↗ | A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | PHASE1 | Recruiting | 2028-09-01 |
| NCT06092034 ↗ | A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease Danon Disease | PHASE2 | Recruiting | 2028-04-01 |
| NCT04248439 ↗ | Gene Therapy for Fanconi Anemia, Complementation Group A Fanconi Anemia Complementation Group A | PHASE2 | Active Not Recruiting | 2026-05-05 |
| NCT07486752 ↗ | BAG3-DCM Natural History Study Dilated Cardiomyopathy (DCM), Cardiovascular Diseases | — | Not Yet Recruiting | 2032-12-01 |
| NCT06422351 ↗ | Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency Pyruvate Kinase Deficiency | PHASE2 | Suspended | 2029-01-01 |
| NCT04105166 ↗ | Gene Therapy for Pyruvate Kinase Deficiency (PKD) Pyruvate Kinase Deficiency | PHASE1 | Completed | 2025-06-09 |
| NCT03882437 ↗ | Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B Danon Disease | PHASE1 | Unknown | 2025-03-24 |
| NCT04069533 ↗ | Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A Fanconi Anemia Complementation Group A | PHASE2 | Unknown | 2025-02-01 |
| NCT05548855 ↗ | Natural History of Danon Disease Danon Disease | — | Completed | 2023-10-31 |
| NCT03812263 ↗ | A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I Leukocyte Adhesion Defect - Type I | PHASE1/PHASE2 | Completed | 2023-09-12 |
| NCT03825783 ↗ | A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I Leukocyte Adhesion Defect - Type I | PHASE1 | Withdrawn | 2021-10-01 |
| NCT04525352 ↗ | A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis Infantile Malignant Osteopetrosis | PHASE1 | Terminated | 2021-05-21 |
| NCT03814408 ↗ | A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A Fanconi Anemia Complementation Group A | PHASE1 | Unknown | 2020-12-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-12 | Acquisition/dispositionReg FDExhibits | filing ↗ |
| 2026-05-21 | Shareholder vote | filing ↗ |
| 2026-05-07 | ResultsExhibits | filing ↗ |
| 2026-04-28 | Material agreementReg FDExhibits | filing ↗ |
| 2026-03-27 | Reg FDExhibits | filing ↗ |
| 2026-03-10 | Material agreement1.02Exhibits | filing ↗ |
| 2026-02-26 | ResultsExhibits | filing ↗ |
| 2025-11-06 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-12 | 2026-06-10 | 0001140361-26-024997 ↗ |
| 8-K | 2026-05-21 | 2026-05-20 | 0001140361-26-022311 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001193125-26-211873 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001140361-26-019573 ↗ |
| 8-K | 2026-04-28 | 2026-04-26 | 0001140361-26-017275 ↗ |
| 8-K | 2026-03-27 | 2026-03-26 | 0001140361-26-011573 ↗ |
| 8-K | 2026-03-10 | 2026-03-10 | 0001140361-26-008853 ↗ |
| 8-K | 2026-02-26 | 2026-02-26 | 0001140361-26-006981 ↗ |
| 10-K | 2026-02-26 | 2025-12-31 | 0001193125-26-076551 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001140361-25-040774 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001193125-25-269474 ↗ |
| 8-K | 2025-10-14 | 2025-10-14 | 0001140361-25-038030 ↗ |